Stock 300181 ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Zhejiang Jolly Pharmaceutical Co.,LTD

Equities

300181

CNE100001096

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
14.93 CNY +1.29% Intraday chart for Zhejiang Jolly Pharmaceutical Co.,LTD -1.65% +40.06%
May. 13 Zhejiang Jolly Pharmaceutical Co.,LTD Announces Director Changes CI
Apr. 19 Zhejiang Jolly Pharmaceutical Co.,LTD announced that it has received CNY 909.999997 million in funding CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Zhejiang Jolly Pharmaceutical Co.,LTD Announces Director Changes
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Declares Dividend for the Year 2023
CI
Zhejiang Jolly Pharmaceutical Co.,LTD announced that it has received CNY 909.999997 million in funding
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang Jolly Pharmaceutical Co.,LTD(XSEC:300181) added to S&P Global BMI Index
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Announces Cash Dividend on A Shares for the Year 2022, Payable on 30 May 2023
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Approves Cash Dividend for 2022
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Final Cash Dividend for the Year 2022
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Zhejiang Jolly Pharmaceutical Co.,LTD signed an equity transfer agreement to acquire the remaining 48.99% stake in Zhejiang Jolly Baicao Chinese Medicine Decoction Pieces Co., Ltd. from Chen Huan and Chen Zhaorong for RMB 75 million.
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 31 May 2022
CI
Zhejiang Jolly Pharmaceutical Co.,LTD completed the acquisition of 8% stake in Zhejiang Top Medicine Co.,Ltd. from Yu Yin.
CI
Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Cash Dividend for 2021
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Cash Dividend for 2021
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Full Year Ended December 31, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300181 Stock
  4. News Zhejiang Jolly Pharmaceutical Co.,LTD